Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Common Equity (2016 - 2025)

OptimizeRx's Common Equity history spans 16 years, with the latest figure at $122.3 million for Q3 2025.

  • For Q3 2025, Common Equity rose 6.81% year-over-year to $122.3 million; the TTM value through Sep 2025 reached $122.3 million, up 6.81%, while the annual FY2024 figure was $117.0 million, 7.55% down from the prior year.
  • Common Equity for Q3 2025 was $122.3 million at OptimizeRx, up from $119.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $140.8 million in Q2 2022 and bottomed at $114.5 million in Q3 2024.
  • The 5-year median for Common Equity is $122.5 million (2024), against an average of $123.6 million.
  • The largest annual shift saw Common Equity soared 186.59% in 2021 before it dropped 17.76% in 2023.
  • A 5-year view of Common Equity shows it stood at $131.4 million in 2021, then decreased by 4.01% to $126.1 million in 2022, then increased by 0.35% to $126.6 million in 2023, then fell by 7.55% to $117.0 million in 2024, then rose by 4.5% to $122.3 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Common Equity are $122.3 million (Q3 2025), $119.3 million (Q2 2025), and $116.3 million (Q1 2025).